Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Oxford Safer Pregnancy Alliance [OSPREA] and the Oxford Vaccine Group [OVG] have recently undertaken a successful recruitment drive for a study of maternal immunisation to prevent infant Respiratory Syncytial Virus [RSV] infection.

This is the first collaboration of its kind in Oxford, and the support provided by the Clinical Research Network Thames Valley and South Midlands has contributed to Oxford being the highest recruiting centre in the United Kingdom for this multinational, multi-centre study.

Babies born to participating mothers will now be followed up by paediatric staff at the Oxford Vaccine Group over winter to see if maternal immunisation is able to protect against this common but potentially life threatening virus. Particular credit should go to all the nurses, doctors, midwives and support staff of the two research teams, and it is expected that this will be the first of many such collaborations.

Similar stories

Oxford vaccine stimulates broad antibody and T cell functions

COVID-19 Publication Research

Researchers from the University of Oxford have published further data from the Phase I/II clinical trials of the ChAdOx1 nCoV-19 coronavirus vaccine, evidencing the decision to move to a two-dose regimen in ongoing phase III trials, and how ChAdOx1 nCov-19 induces broad antibody and T cell functions.

SIMON Says…

Publication Research

Researchers at Oxford Vaccine Group have developed machine learning software to predict the efficacy of flu vaccines, offering huge potential for other vaccine research.

Trial of Oxford COVID-19 vaccine in South Africa begins

COVID-19 Research

Participants in South Africa’s first clinical trial for a vaccine against COVID-19 are to be vaccinated this week.

Trial of Oxford COVID-19 vaccine starts in Brazil

COVID-19 Research

Volunteers have begun taking part in Latin America’s first clinical trial for a vaccine against COVID-19.

AstraZeneca to supply Europe with up to 400 million doses of Oxford University’s vaccine at no profit

COVID-19 Research

AstraZeneca has reached an agreement with Europe’s Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses of the University of Oxford’s COVID-19 vaccine, with deliveries starting by the end of 2020.